TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24708643

Group type: EXPERIMENTAL
Intervention: Semi-standardised acupuncture plus rescue medication (cetirizine)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Sham acupuncture plus rescue medication (cetirizine)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Rescue medication (cetirizine) alone
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 422
Study: 23046781

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) with written accounts (WA) component
Number of subjects: 0
Study: 20367631

Group type: EXPERIMENTAL
Intervention: GM-CSF applications
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 17608342

Group type: EXPERIMENTAL
Intervention: Dynesys dynamic stabilization system
Number of subjects: 101
Study: 16275187

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 64
Study: 12366861

Group type: EXPERIMENTAL
Intervention: Chlorhexidine chip + Scaling and Root Planing (Sc/Rp)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Scaling and Root Planing (Sc/Rp)
Number of subjects: 13
Study: 10428194

Group type: EXPERIMENTAL
Intervention: Counseling trial participation
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Media contacts
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Cancer worry
Number of subjects: 588
Study: 7503597

Group type: EXPERIMENTAL
Intervention: Fecal occult blood test (FOBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current methods for colorectal cancer screening
Number of subjects: 0
Study: 2097305

Group type: EXPERIMENTAL
Intervention: Nifedipine (80 mg/day)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study: 7460803

Group type: EXPERIMENTAL
Intervention: Partial plasma exchange transfusion
Number of subjects: 49

Group type: COMPARATOR
Intervention: Hyperviscous (no intervention)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 49
Study: 30419799

Group type: EXPERIMENTAL
Intervention: Younger maternal age
Number of subjects: 1653
Study: 29855803

Group type: EXPERIMENTAL
Intervention: Aerobic training (AT) 3 times per week for 8 weeks at 60-75% VO2peak
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (CON) refrained from any exercise training
Number of subjects: 24
Study: 26910107

Group type: EXPERIMENTAL
Intervention: 1.2 mg liraglutide
Number of subjects: 11
Study: 24509894

Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray (80 IU a day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 14
Study: 22216936

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention
Number of subjects: 573

Group type: COMPARATOR
Intervention: Control group (Project Toward No Drug Abuse)
Number of subjects: 573
Study: 19462850

Group type: EXPERIMENTAL
Intervention: Bovine pericardium
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Equine pericardium
Number of subjects: 52

Group type: COMPARATOR
Intervention: Autologous temporalis fascia
Number of subjects: 52
Study: 17448056

Group type: EXPERIMENTAL
Intervention: 30 N cricoid pressure
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham cricoid pressure
Number of subjects: 120
Study: 15345791

Group type: EXPERIMENTAL
Intervention: Hormone therapy (estrogen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reinstitution of estrogen or initiation/increase in antidepressant dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discontinuation of hormone therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hormone therapy (estrogen) or selective estrogen receptor modulator
Number of subjects: 0
Study: 12393356

Group type: EXPERIMENTAL
Intervention: Sufentanil 7.5 microg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sufentanil 7.5 microg + epinephrine 200 microg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sufentanil 7.5 microg + clonidine 30 microg
Number of subjects: 45
Study: 10439645

Group type: COMPARATOR
Intervention: Thiopental 5 mg·kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Etomidate 0.3 mg·kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 40
Study: 7598439

Group type: COMPARATOR
Intervention: WHO/UNICEF oral rehydration solution (ORS)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Fermented maize solution
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Unfermented maize solution
Number of subjects: 108
Study: 1694158

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% and adrenaline 1:80000 without HES
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lidocaine 2% and adrenaline 1:80000 with 10% HES 200/0.5
Number of subjects: 20
Study: 25847

Group type: EXPERIMENTAL
Intervention: Trimepranol (TMP)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 30365231

Group type: EXPERIMENTAL
Intervention: Virtual reality group (4-minute virtual reality video)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (conventional education regarding perioperative process)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Virtual reality group
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study: 28824012

Group type: EXPERIMENTAL
Intervention: 3.0 g of CLA daily for 3 months
Number of subjects: 74

Group type: COMPARATOR
Intervention: Sunflower oil as placebo daily for 3 months
Number of subjects: 74
Study: 25755251

Group type: EXPERIMENTAL
Intervention: Fat emulsion (Group A)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Saline (Group A)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Fat emulsion (Group B)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Saline (Group B)
Number of subjects: 128
Study: 23496092

Group type: EXPERIMENTAL
Intervention: I : E ratio of 1 : 1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: I : E ratio of 2 : 1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: I : E ratio of 1 : 2 PEEP
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional I : E ratio (Group 1 : 2)
Number of subjects: 100
Study: 20963405

Group type: EXPERIMENTAL
Intervention: Biolimus A9 eluted from BioMatrix II stents
Number of subjects: 27
Study: 19058760

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Active treatment (Labetalol and Lisinopril combined)
Number of subjects: 179
Study: 17204269

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 16

Group type: COMPARATOR
Intervention: Western diet
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low fat diet enriched in alpha‐linolenic acid
Number of subjects: 16
Study: 15028365

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 533

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 533
Study: 14763721

Group type: EXPERIMENTAL
Intervention: Day service attendance for six months
Number of subjects: 26

Group type: COMPARATOR
Intervention: No attendance for six months
Number of subjects: 26
Study: 10999088

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid-adenosine deaminase (CSF-ADA) activity in TBM patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cerebrospinal fluid-adenosine deaminase (CSF-ADA) activity in non-TBM patients (viral encephalitis and enteric encephalopathy)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cerebrospinal fluid-adenosine deaminase (CSF-ADA) activity in pyogenic meningitis
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cerebrospinal fluid-adenosine deaminase (CSF-ADA) activity in cerebral malaria
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diagnosis of TBM using CSF-ADA levels
Number of subjects: 60
Study: 7741285

Group type: EXPERIMENTAL
Intervention: Thiobarbiturate (5 mg/kg thiopental or thiamylal)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Oxybarbiturate (1.75 mg/kg methohexital)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg/kg)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Thiobarbiturate (5 mg/kg)
Number of subjects: 155
Study: 2201652

Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (LAC) 2 g/day
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 6259941

Group type: EXPERIMENTAL
Intervention: Ointment containing polymyxin, neomycin and bacitracin (PNB)
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: Iodophor ointment (PI2)
Number of subjects: 827

Group type: COMPARATOR
Intervention: No topical agent (Control)
Number of subjects: 827

Group type: COMPARATOR
Intervention: Control
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: PI2
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: PNB
Number of subjects: 827
Study: 31593697

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31825772

Group type: EXPERIMENTAL
Intervention: TLC-NOSF dressing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral dressing (control)
Number of subjects: 0
Study: 27845030

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided capsule-preserved hydrodilatation with corticosteroid (1mL of 40mg/mL triamcinolone acetonide, 6mL of 1% lidocaine, and normative saline)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Ultrasound-guided IACI alone (1mL of 40mg/mL triamcinolone acetonide and 3mL of 1% lidocaine)
Number of subjects: 64
Study: 26353875

Group type: EXPERIMENTAL
Intervention: Intranasal 2% mupirocin plus topical antisepsis with chlorhexidine gluconate for 5 days
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo ointment and placebo cloths for skin antisepsis for 5 days
Number of subjects: 400
Study: 24165586

Group type: EXPERIMENTAL
Intervention: Cotransplantation of CB and ex vivo expanded UCMSCs
Number of subjects: 20

Group type: COMPARATOR
Intervention: CBT alone
Number of subjects: 20
Study: 21890077

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DESs) in patients with normal GFR (≥60 ml/min/1.73 m²)
Number of subjects: 4157

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DESs) in patients with low GFR (<60 ml/min/1.73 m²)
Number of subjects: 4157

Group type: COMPARATOR
Intervention: Bare-metal stents in patients with low GFR (<60 ml/min/1.73 m²)
Number of subjects: 4157

Group type: COMPARATOR
Intervention: Bare-metal stents in patients with normal GFR (≥60 ml/min/1.73 m²)
Number of subjects: 4157
Study: 19295193

Group type: EXPERIMENTAL
Intervention: Low fat diet
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Number of subjects: 193
Study: 17449421

Group type: EXPERIMENTAL
Intervention: Daclizumab (DZM)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Anti-thymocyte globulin (ATG)
Number of subjects: 50
Study: 15328386

Group type: EXPERIMENTAL
Intervention: ET-1 (2.5 ng/kg/min)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: VML 588 (0.05, 0.20 and 0.40 mg/kg/h)
Number of subjects: 9
Study: 11418315

Group type: EXPERIMENTAL
Intervention: 90Y Zevalin (0.4 mCi/kg therapeutic dose after 5 mCi tracer dose)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Rituximab (375 mg/m2 weekly x 4)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 90Y Zevalin
Number of subjects: 90
Study: 9593559

Group type: EXPERIMENTAL
Intervention: Early complete reperfusion (TIMI grade 3)
Number of subjects: 2431

Group type: EXPERIMENTAL
Intervention: Ejection fraction >40%
Number of subjects: 2431
Study: 7925872

Group type: EXPERIMENTAL
Intervention: Exposure to dust and solvents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probability of exposure to dust
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time-related estimates of exposure to dust based on work history
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Full work history to determine exposure to dust
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure to wood dust
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High probability of exposure to dust
Number of subjects: 0

Group type: COMPARATOR
Intervention: None of the exposures
Number of subjects: 0
Study: 29728552

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No laser therapy (Control)
Number of subjects: 10
Study: 27741335

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab every-other-week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24740207

Group type: EXPERIMENTAL
Intervention: rs7041 SNP (T allele)
Number of subjects: 1380

Group type: EXPERIMENTAL
Intervention: rs705117 SNP (G allele)
Number of subjects: 1380

Group type: EXPERIMENTAL
Intervention: rs12144344 SNP
Number of subjects: 1380
Study: 23414650

Group type: EXPERIMENTAL
Intervention: CTC
Number of subjects: 1610

Group type: COMPARATOR
Intervention: Colonoscopy
Number of subjects: 1610
Study: 21388079

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Hydroxyzine 75 mg
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 19477772

Group type: EXPERIMENTAL
Intervention: Descending alcohol intoxication (from .08%) with instruction to maximize arousal
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Descending alcohol intoxication (from .08%) with instruction to suppress arousal
Number of subjects: 78

Group type: COMPARATOR
Intervention: Sober men with instruction to maximize arousal
Number of subjects: 78
Study: 16431031

Group type: EXPERIMENTAL
Intervention: Nonsmoking women postpartum (protected, high risk, premature, ambivalent groups)
Number of subjects: 317
Study: 14612643

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 64

Group type: COMPARATOR
Intervention: Cyclosporin A
Number of subjects: 64
Study: 10913225

Group type: EXPERIMENTAL
Intervention: Arachidonic acid (AA) 300 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Combination of AA (300 mg), EPA (110 mg), and DHA (400 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Unsupplemented control
Number of subjects: 26
Study: 8704095

Group type: EXPERIMENTAL
Intervention: Interleukin-1 beta
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor-alpha
Number of subjects: 40
Study: 1526682

Group type: EXPERIMENTAL
Intervention: Cefodizime (CDZ) 2 g i.v. once daily for seven days
Number of subjects: 51

Group type: COMPARATOR
Intervention: Ascorbic acid 1 g daily i.v. for one week (Control)
Number of subjects: 51
Study: 4035227

Group type: EXPERIMENTAL
Intervention: sulodexide
Number of subjects: 0
Study: 30708260

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 8
Study: 29672831

Group type: EXPERIMENTAL
Intervention: 100 mg riluzole
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 300 mg retigabine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 26969416

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5 to 40 mg
Number of subjects: 15800

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 to 40 mg
Number of subjects: 15800

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 15800

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 and 40 mg
Number of subjects: 15800
Study: 24207098

Group type: EXPERIMENTAL
Intervention: Intra-arterial clot retrieval with the Solitaire FR device after intravenous tissue plasminogen activator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous tissue plasminogen activator alone
Number of subjects: 0
Study: 22354851

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 1274

Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 1274
Study: 20385940

Group type: EXPERIMENTAL
Intervention: 20-millisecond Pascal PRP
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 100-millisecond Pascal PRP
Number of subjects: 24
Study: 18724539

Group type: EXPERIMENTAL
Intervention: gemcitabine (Gemzar) plus 3 mg/kg of infliximab (Remicade)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: gemcitabine (Gemzar) plus 5 mg/kg of infliximab (Remicade)
Number of subjects: 86

Group type: COMPARATOR
Intervention: gemcitabine (Gemzar) plus placebo
Number of subjects: 86
Study: 16521701

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1,800 mg/d with vitamin E 300 mg/d and vitamin C 600 mg/d
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (vitamin E 300 mg/d and vitamin C 600 mg/d without EPA)
Number of subjects: 10
Study: 12173322

Group type: EXPERIMENTAL
Intervention: Repeat screening flexible sigmoidoscopy
Number of subjects: 10164
Study: 10459062

Group type: EXPERIMENTAL
Intervention: Intravesical application of 5‐aminolevulinic acid (5‐ALA)
Number of subjects: 0
Study: 7843707

Group type: EXPERIMENTAL
Intervention: PGE1 (40 micrograms/h)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 2370508

Group type: EXPERIMENTAL
Intervention: Large cuff (15 X 33 cm)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Small cuff (12 X 23 cm)
Number of subjects: 242
Study: 654296

Group type: EXPERIMENTAL
Intervention: Phenformin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Buformin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Discontinuation of biguanide treatment
Number of subjects: 10
Study: 31950141

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD) for 8 weeks
Number of subjects: 209

Group type: COMPARATOR
Intervention: Weight loss maintenance diets based on protein and glycemic index content
Number of subjects: 209
Study: 30621974

Group type: EXPERIMENTAL
Intervention: Aspirin + ticagrelor
Number of subjects: 68

Group type: COMPARATOR
Intervention: Aspirin + clopidogrel
Number of subjects: 68

Group type: COMPARATOR
Intervention: Registry cohort (Aspirin + clopidogrel)
Number of subjects: 68
Study: 29047326

Group type: EXPERIMENTAL
Intervention: Integration of Community Health Workers (CHWs) in diabetes group visits
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no CHWs)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intervention group (with CHWs)
Number of subjects: 50
Study: 26324329

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg/day add-on to dapagliflozin plus metformin
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo add-on to dapagliflozin plus metformin
Number of subjects: 315
Study: 24929184

Group type: EXPERIMENTAL
Intervention: Low flavanol apple puree (25 mg epicatechin)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High flavanol apple puree (100 mg epicatechin)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Aspirin (75 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both low and high flavanol apple purees
Number of subjects: 25
Study: 23033226

Group type: EXPERIMENTAL
Intervention: Pharmacist-led warfarin self-management program
Number of subjects: 114

Group type: COMPARATOR
Intervention: Standard management at the anticoagulation clinic
Number of subjects: 114
Study: 19900743

Group type: EXPERIMENTAL
Intervention: Peer evaluation group (students evaluated each other's performance before switching roles)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (students worked in a defined doer-helper relationship without peer evaluation)
Number of subjects: 78
Study: 17641565

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (minimum of four needles, electroacupuncture preferred, strong electrical stimulation to needles placed in muscle, course of at least 10 treatments)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 13
Study: 15882556

Group type: EXPERIMENTAL
Intervention: Caffeine 300 mg/day
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 12522677

Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy with carboplatin plus ACNU (arm A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous chemotherapy with cisplatin plus BCNU (arm B)
Number of subjects: 30
Study: 10321140

Group type: EXPERIMENTAL
Intervention: Headgear
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fränkel functional appliance
Number of subjects: 0
Study: 7664215

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily
Number of subjects: 3700

Group type: EXPERIMENTAL
Intervention: Losartan 50 to 100 mg once daily
Number of subjects: 3700

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily + 12.5 mg HCTZ
Number of subjects: 3700

Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 3700
Study: 2693078

Group type: EXPERIMENTAL
Intervention: 4 liters of Golytely
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 2 liters of Golytely combined with Cascara‐Salax
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: X‐Prep (a Senna preparation) combined with an enema
Number of subjects: 300
Study: 354042

Group type: EXPERIMENTAL
Intervention: Single daily doses of acebutolol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of acebutolol with chlorexolone
Number of subjects: 20
Study: 29923537

Group type: EXPERIMENTAL
Intervention: Exposure to second-hand smoke at home in urban areas, females, low educational status, and nongovernment employees
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Exposure to second-hand smoke at workplace in rural areas, males, primary and middle education, and nongovernment or self‐employed occupation
Number of subjects: 510
Study: 27037905

Group type: EXPERIMENTAL
Intervention: Primary trabeculotomy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Combined trabeculectomy-trabeculotomy (CTT) with mitomycin C (MMC)
Number of subjects: 28
Study: 24891081

Group type: EXPERIMENTAL
Intervention: Induced night-wakings (four prolonged awakenings across 8h in bed)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Sleep restriction (4h in bed)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Normal sleep night
Number of subjects: 61
Study: 22702049

Group type: EXPERIMENTAL
Intervention: Vacuum sealing drainage (VSD) combined with anti-taken skin graft
Number of subjects: 60

Group type: COMPARATOR
Intervention: Direct anti-taken skin graft (control)
Number of subjects: 60